KRT1 and cancer: The PDCs with K1 targeting peptide 18-4 were more cytotoxic to TNBC cells (IC50 1.2–4.7 μM) compared to non-cancerous human mammary epithelial MCF-10A cells (IC50 15.1–38.6 μM), while free drug (doxorubicin) was equally cytotoxic to both cancer and non-cancerous cells (IC50 0.24–1.5 μM) [29].